225 related articles for article (PubMed ID: 34545802)
21. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
23. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.
Kofteridis DP; Valachis A; Velegraki M; Antoniou M; Christofaki M; Vrentzos GE; Andrianaki AM; Samonis G
J Infect Chemother; 2014 Jul; 20(7):412-6. PubMed ID: 24767467
[TBL] [Abstract][Full Text] [Related]
24. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.
Otani T; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Pulm Pharmacol Ther; 2021 Apr; 67():101999. PubMed ID: 33571651
[TBL] [Abstract][Full Text] [Related]
26. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
[No Abstract] [Full Text] [Related]
27. [Pneumocystis pneumonia in a renal transplant recipient].
Özkoç S; İnceboz T; Sıfıl A; Tuncay S; Akisü Ç
Turkiye Parazitol Derg; 2010; 34(4):186-9. PubMed ID: 21391190
[TBL] [Abstract][Full Text] [Related]
28. Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients: systematic review and individual patient data meta-analysis.
Passerini M; Nayfeh T; Yetmar ZA; Coussement J; Goodlet KJ; Lebeaux D; Gori A; Mahmood M; Temesgen Z; Murad MH
Clin Microbiol Infect; 2024 Feb; 30(2):170-177. PubMed ID: 37865337
[TBL] [Abstract][Full Text] [Related]
29. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
[TBL] [Abstract][Full Text] [Related]
30. [Infection prophylaxis in patients with hematological malignancies (I)--Successful prophylaxis of Pneumocystis carinii pneumonitis with sulfamethoxazole-trimethoprim].
Moriuchi Y; Kamihira S; Satoh T; Yanagisako T; Miyazaki Y; Nagai K; Murata K; Tokunaga S; Maeda T; Atogami S
Rinsho Ketsueki; 1990 Nov; 31(11):1818-22. PubMed ID: 2287067
[TBL] [Abstract][Full Text] [Related]
31. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
Carr A; Tindall B; Penny R; Cooper DA
AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
[TBL] [Abstract][Full Text] [Related]
32. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
Anand S; Samaniego M; Kaul DR
Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary nocardiosis caused by Nocardia exalbida complicating Pneumocystis pneumonia in an HIV-infected patient.
Imai K; Koibuchi T; Kikuchi T; Koga M; Nakamura H; Miura T; Gonoi T; Yazawa K; Iwamoto A; Fujii T
J Infect Chemother; 2011 Aug; 17(4):547-51. PubMed ID: 21249414
[TBL] [Abstract][Full Text] [Related]
34. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?
Redjoul R; Robin C; Foulet F; Leclerc M; Beckerich F; Cabanne L; di Blasi R; Pautas C; Toma A; Botterel F; Maury S; Cordonnier C
Bone Marrow Transplant; 2019 Jul; 54(7):1082-1088. PubMed ID: 30413810
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults.
Zhou S; Aitken SL
JAMA; 2023 Jul; 330(2):182-183. PubMed ID: 37358837
[TBL] [Abstract][Full Text] [Related]
36. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
Tritle BJ; Hejazi AA; Timbrook TT
Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
[TBL] [Abstract][Full Text] [Related]
38. Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Molina A; Winston DJ; Pan D; Schiller GJ
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1715-1720. PubMed ID: 29555315
[TBL] [Abstract][Full Text] [Related]
39. Effects of Sulfamethoxazole-Trimethoprim on Airway Colonization with Pneumocystis jirovecii.
Kushima H; Ishii H; Tokimatsu I; Umeki K; Sato T; Kadota J
Jpn J Infect Dis; 2016 May; 69(3):252-5. PubMed ID: 26255727
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
